Pfizer’s Finance Leader Moves to Consumer Goods

Key Dates

• August 15: Dave Denton departs Pfizer.
• August 16: Cecile Guegan assumes interim CFO duties.

Executive Movement

Pfizer’s chief financial officer, Dave Denton, will leave the company to pursue a new opportunity in the consumer goods sector. Denton joined Pfizer’s finance team in 2022, bringing experience from CVS and Lowe’s. His departure follows a successful tenure that saw the company acquire Seagen, Biohaven, and Metsera, expanding its oncology, neurology, and obesity portfolios.

Interim Leadership

Cecile Guegan—currently head of finance for Pfizer’s global biopharmaceutical division—will step in as interim CFO. She is tasked with guiding the firm through this transition while a permanent successor is identified both internally and externally.

Market Reaction

The announcement caused a modest dip in Pfizer’s stock, with shares falling 1.6% in pre‑market trading. Investors are keen to see how the company maintains financial stability amid this leadership change.

Leadership Praise

CEO Albert Bourla commended Denton for steering the company through complex transactions. Pfizer emphasized that Denton and Guegan will collaborate closely to ensure a seamless handover of responsibilities.